Tharimmune, Inc. - Common Stock (THAR)

About Tharimmune, Inc. - Common Stock (THAR)

Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for inflammation and immunology. It also develops TH104, which is known to suppress chronic, debilitating pruritus or uncontrollable itching in PBC, a rare and orphan liver disease with no known cure. The company was founded on March 28, 2017 and is headquartered in Bridgewater, NJ.

Tharimmune, Inc. - Common Stock News